Caribou Biosciences

CRBU · NASDAQ

$0.519+$0.055 (+11.85%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $0.464

Latest news

NewsOct 9, 3:03 PM ETCaroline Ryan
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
NewsOct 8, 8:07 AM ETAvi Kapoor
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
NewsOct 7, 12:02 PM ETAvi Kapoor
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
NewsOct 7, 9:52 AM ETAvi Kapoor
Dow Tumbles 350 Points; Constellation Brands Earnings Top Views
NewsOct 7, 8:36 AM ETRishabh Mishra
Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall as 30-Year Treasury Yield Hits 2002 High; Iran Mocks US Economy — STZ, PENG, LEVI in Focus (UPDATED)
NewsOct 7, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsOct 7, 8:02 AM ETAvi Kapoor
Constellation Brands, Caribou Biosciences And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
NewsOct 7, 4:38 AM ETAvi Kapoor
Why Penguin Solutions Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
NewsOct 7, 2:27 AM ETAvi Kapoor
Levi Strauss, Constellation Brands and 3 Stocks to Watch Heading Into Wednesday
NewsOct 7, 1:34 AM ETTanya Rawat
Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's Why
NewsOct 6, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseAug 13, 4:05 PM ETGlobe Newswire
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseJun 12, 8:10 AM ETGlobe Newswire
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
Press releaseJun 11, 8:01 AM ETGlobe Newswire
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
Press releaseJun 11, 8:00 AM ETGlobe Newswire
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
Press releaseMay 12, 9:30 AM ETGlobe Newswire
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
Press releaseMay 7, 4:05 PM ETGlobe Newswire
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Press releaseMar 31, 8:00 AM ETGlobe Newswire
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
NewsMar 5, 4:10 PM ET
Insights into Caribou Biosciences Q4 Earnings
Press releaseMar 5, 4:05 PM ETGlobe Newswire
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Press releaseFeb 4, 8:00 AM ETGlobe Newswire
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
Press releaseDec 24, 6:00 AM ETGlobe Newswire
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Press releaseNov 12, 4:05 PM ETGlobe Newswire
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
NewsNov 3, 11:48 AM ETVandana Singh
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>
NewsNov 3, 7:05 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsNov 3, 5:09 AM ETAvi Kapoor
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
Press releaseJul 25, 7:35 PM ETGlobe Newswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NewsJun 20, 1:59 PM ETVandana Singh
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
Press releaseMar 10, 4:05 PM ETGlobe Newswire
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Press releaseMar 6, 9:00 PM ETGlobe Newswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Press releaseFeb 24, 5:05 PM ETPRNewswire
CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit
Press releaseFeb 24, 5:45 AM ETPRNewswire
Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU
Press releaseFeb 21, 5:45 AM ETPRNewswire
February 24, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CRBU
Press releaseFeb 20, 9:53 AM ETPRNewswire
Faruqi & Faruqi Reminds Caribou Biosciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025 - CRBU
Press releaseFeb 20, 5:45 AM ETPRNewswire
Caribou Biosciences, Inc. Class Action: The Gross Law Firm Reminds Caribou Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025 - CRBU
Press releaseFeb 19, 6:37 PM ETPRNewswire
CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit
Press releaseFeb 19, 10:22 AM ETGlobe Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
Press releaseFeb 18, 6:21 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Caribou Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - CRBU
Press releaseFeb 18, 5:45 AM ETPRNewswire
Shareholders of Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU
Press releaseFeb 15, 3:04 PM ETBusiness Wire
CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights
Press releaseFeb 14, 1:22 PM ETPRNewswire
CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit
Press releaseFeb 14, 5:45 AM ETPRNewswire
Class Action Filed Against Caribou Biosciences, Inc. (CRBU) - February 24, 2025 Deadline to Join - Contact Levi & Korsinsky
Press releaseFeb 13, 11:08 AM ETPRNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
Press releaseFeb 13, 5:45 AM ETPRNewswire
Caribou Biosciences, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU
NewsNov 26, 4:06 PM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy

Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

Nasdaq Falls Over 100 Points; US Crude Inventories Decline

Dow Tumbles 350 Points; Constellation Brands Earnings Top Views

Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall as 30-Year Treasury Yield Hits 2002 High; Iran Mocks US Economy — STZ, PENG, LEVI in Focus (UPDATED)

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Constellation Brands, Caribou Biosciences And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Why Penguin Solutions Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Levi Strauss, Constellation Brands and 3 Stocks to Watch Heading Into Wednesday

Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's Why

12 Health Care Stocks Moving In Tuesday's After-Market Session

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Insights into Caribou Biosciences Q4 Earnings

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>

12 Health Care Stocks Moving In Monday's Pre-Market Session

Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

February 24, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CRBU

Faruqi & Faruqi Reminds Caribou Biosciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025 - CRBU

Caribou Biosciences, Inc. Class Action: The Gross Law Firm Reminds Caribou Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025 - CRBU

CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Caribou Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - CRBU

Shareholders of Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU

CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights

CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit

Class Action Filed Against Caribou Biosciences, Inc. (CRBU) - February 24, 2025 Deadline to Join - Contact Levi & Korsinsky

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Caribou Biosciences, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

12 Health Care Stocks Moving In Tuesday's Pre-Market Session